Research programme: synthetic macrocycles - Ensemble Therapeutics/Novartis
Latest Information Update: 14 Aug 2013
At a glance
- Originator Ensemble Therapeutics; Novartis
- Class Macrocyclic compounds; Small molecules
- Mechanism of Action Protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 06 Aug 2013 Early research in Undefined indication in USA (unspecified route)